[Paraneoplastic syndromes in lung cancer].
Paraneoplastic syndromes occur in approximately 10% of all patients with lung cancer. They can be the first manifestation of the disease or of a recurrence. Endocrine, haematological, neuromuscular, dermatological, renal, and metabolic syndromes as well as syndromes involving the connective tissue and constitutional syndromes can be distinguished based on their clinical symptoms. In this review, the epidemiology, pathogenesis, clinical signs and treatment options for the clinically important paraneoplastic syndromes in lung cancer are discussed.
Medizinische Klinik, Forschungszentrum Borstel, Parkallee 35, Borstel. hphauber@fz-borstel.de
H-P
HP
Hauber
D003430:Cross-Sectional Studies; D006801:Humans; D015994:Incidence; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D010257:Paraneoplastic Syndromes / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D011379:Prognosis; D012307:Risk Factors